17,881 resources
By Version
By Realm
Start Prev Rows 12600 - 12800 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Realm | Source(s) |
|---|---|---|---|---|---|---|---|---|---|
| hl7.cda.uv.ips | R4 | 2.16.840.1.113883.11.22.54--20170718000000 | IPS Personal Relationship | draft | 2024-08 | uv | tho | ||
| hl7.fhir.uv.ips | R4 | personal-relationship-uv-ips | Personal Relationship - IPS [Deprecated] | trial-use | 2 | pc | 2025-08 | uv | tho |
| hl7.fhir.eu.eps | R4 | eHDSISeverity | Severity | active | 2025-06 | eu | sct | ||
| hl7.fhir.cz.hdr | R4 | eHDSIConditionPOA | eHDSI Condition Present On Admission | draft | 1 | 2025-08 | cz | sct | |
| hl7.fhir.eu.hdr | R4 | eHDSIConditionPOA | eHDSI Condition Present On Admission | draft | 1 | 2025-06 | eu | sct | |
| hl7.fhir.cz.hdr | R4 | eHDSITreatmentClass | eHDSI Treatment Class | draft | 1 | 2025-08 | cz | sct | |
| hl7.fhir.eu.hdr | R4 | eHDSITreatmentClass | eHDSI Treatment Class | draft | 1 | 2025-06 | eu | sct | |
| hl7.fhir.us.pq-cmc-fda | R5 | pqcmc-analytical-instrument-data-types | Analytical Instrument Data File Types | trial-use | 2 | brr | 2025-07 | us | ietf |
| hl7.fhir.us.pq-cmc-fda | R5 | pqcmc-structure-data-types | Structure Data Types | trial-use | 2 | brr | 2025-07 | us | ietf |
| hl7.fhir.us.pq-cmc-fda | R5 | pqcmc-graphical-file-types | Graphical File Types | trial-use | 2 | brr | 2025-07 | us | ietf |
| hl7.terminology | R5 | v3-ActClassReview | ActClassReview | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ActClassSubstanceAdministration | ActClassSubstanceAdministration | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ActClassStorage | ActClassStorage | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ActClassInform | ActClassInform | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ActClassExposure | ActClassExposure | active | 2014-03 | uv | tho | ||
| hl7.fhir.fr.core | R4 | fr-core-vs-organization-activity-field | FR Core ValueSet Organization activity field | informative | 5 | pc | 2024-09 | fr | |
| hl7.terminology | R5 | v3-Other | Other | active | 2014-03 | uv | tho | ||
| ch.fhir.ig.ch-vacd | R4 | ch-vacd-immunization-allergyintolerances-vs | Allergies and Intolerance values for Immunization | draft | 2025-05 | ch | sct | ||
| hl7.fhir.uv.extensions | R5 | dataelement-sdcobjectclassproperty | DataElement SDC Object Class Property | trial-use | 3 | fhir | 2023-01 | uv | sct rx loinc |
| hl7.fhir.uv.extensions | R5 | dataelement-sdcobjectclass | DataElement SDC Object Class | trial-use | 3 | fhir | 2023-01 | uv | sct rx loinc |
| hl7.fhir.us.sdcde | R3 | dataelement-sdccode | DataElement SDC Concept | draft | 2017-04 | us | sct rx loinc | ||
| hl7.fhir.uv.sdc | R4 | sdc-profile-example | SDC-ValueSet AHRQ_Medication_Q1 | active | fhir | 2014-01 | uv | loinc | |
| hl7.terminology | R5 | certainty-type | Evidence Certainty Type | trial-use | 1 | cds | 2025-01 | uv | tho |
| hl7.fhir.uv.extensions.r3 | R3 | certainty-type | Evidence Certainty Type | trial-use | 1 | cds | 2020-12 | uv | fhir |
| hl7.fhir.uv.extensions.r3 | R3 | certainty-rating | Evidence Certainty Rating | trial-use | 1 | cds | 2020-12 | uv | fhir |
| hl7.terminology | R5 | v3-ContextControlAdditivePropagating | ContextControlAdditivePropagating | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ContextControlOverriding | ContextControlOverriding | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ContextControlAdditiveNon-propagating | ContextControlAdditiveNon-propagating | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ContextControlAdditive | ContextControlAdditive | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ContextControlNonPropagating | ContextControlNonPropagating | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ContextControlOverridingNon-propagating | ContextControlOverridingNon-propagating | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ContextControlOverridingPropagating | ContextControlOverridingPropagating | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ContextControlPropagating | ContextControlPropagating | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v2-0962 | FHIRdeviceStatus | active | 2019-12 | uv | fhir | ||
| hl7.terminology | R5 | device-status-reason | FHIRDeviceStatusReason | draft | 2 | oo | 2020-02 | uv | tho |
| hl7.terminology | R5 | v3-xActInvoiceDetailPharmacyCode | x_ActInvoiceDetailPharmacyCode | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-xActInvoiceDetailPreferredAccommodationCode | x_ActInvoiceDetailPreferredAccommodationCode | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ActInvoiceDetailGenericAdjudicatorCode | ActInvoiceDetailGenericAdjudicatorCode | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ActInvoiceDetailTaxCode | ActInvoiceDetailTaxCode | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ActInvoiceDetailGenericModifierCode | ActInvoiceDetailGenericModifierCode | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ActInvoiceDetailGenericProviderCode | ActInvoiceDetailGenericProviderCode | active | 2014-03 | uv | tho | ||
| hl7.fhir.uv.genomics-reporting | R4 | molecular-consequence-vs | Molecular Consequence Value Set | trial-use | 2 | cg | 2025-06 | uv | |
| nhsd.assets.stu3 | R3 | ValueSet-NDOP-OptOutCategory-1 | Opt Out Category | draft | 2018-01 | ||||
| ch.fhir.ig.ch-crl | R4 | nkrs-circumferentialresectionmargins | NKRS - Circumferential Resection Margins | active | 2022-02 | ch | internal | ||
| hl7.fhir.uv.extensions | R5 | subject-locationClassification | An example set of classifications of the location of the subject in an Encounter | draft | pa | 2025-08 | uv | fhir | |
| signal.core.r4 | R4 | questionnaire-ccars-tobacco-use | Questionnaire CCARS Tobacco Use | draft | 1 | pa | us | ||
| ca.on.oh.mha-pds | R4 | ValueSet.ca-on-mha-LegalStatus | Legal Status | active | 2022-08 | ca | tho | ||
| ca.on.oh.mha-pds | R4 | ValueSet.ca-on-mha-PersonalIncomeSource | Personal Income Source | active | 2022-08 | ca | sct tho | ||
| ca.on.oh.mha-pds | R4 | vs-EmploymentStatus-v1 | Employment Status | active | 2022-08 | ca | sct tho | ||
| nhsd.assets.stu3 | R3 | DCH-RequestPriority-1 | RequestPriority | draft | 3 | pc | 2017-04 | fhir | |
| signal.core.r4 | R4 | request-priority | RequestPriority | draft | 3 | pc | 2016-07 | us | fhir |
| hl7.terminology | R5 | v3-AllergyStatus | Allergy Status | active | 2019-03 | uv | sct | ||
| nhsd.assets.stu3 | R3 | GPConnect-RequestPriority-1 | GPConnect Request Priority | draft | 3 | pc | 2020-07 | fhir | |
| hl7.terminology | R5 | v3-MapRelationship | MapRelationship | active | 2014-03 | uv | tho | ||
| hl7.fhir.us.davinci-pas | R4 | PASTaskCodes | PAS Task Codes | trial-use | 3 | fm | 2025-07 | us | fhir |
| fhir.org.nz.ig.base | R4 | practitioner-registration-status-code | Registration Status of Practitioners | active | 2025-06 | us | |||
| hl7se.fhir.base | R4 | SEBaseSOSNYKVS | ValueSet for occupation codes from the National Board of Health and Welfare (SOSNYK) | active | 2025-06 | se | oid | ||
| hl7se.fhir.base | R4 | SEBaseHSABefattningVS | Valueset for HSA occupational positions in healthcare | active | 2025-06 | se | oid | ||
| hl7.fhir.us.vrdr | R4 | vrdr-death-certification-event-vs | Event Code for Death Certificate Composition | active | pher | 2024-10 | us | sct | |
| hl7.terminology | R5 | service-provision-conditions | ServiceProvisionConditions | active | 1 | pa | 2024-04 | uv | tho |
| signal.core.r4 | R4 | service-provision-conditions | ServiceProvisionConditions | draft | 1 | pa | 2019-10 | us | tho |
| hl7.fhir.uv.sdc | R4 | task-code | SDC Task Code | trial-use | 4 | fhir | 2025-08 | uv | fhir |
| ch.fhir.ig.ch-vacd | R4 | ch-vacd-basic-immunization-vs | Basic Immunization Codes | active | 2025-05 | ch | internal | ||
| ch.fhir.ig.ch-vacd | R4 | ch-vacd-entry-conflict-vs | Entry Conflict Codes | active | 2025-05 | ch | internal | ||
| signal.core.r4 | R4 | omb-race-category | OMB Race Categories | active | 2022-09 | us | vsac | ||
| signal.core.r4 | R4 | detailed-ethnicity | Detailed ethnicity | active | 2022-09 | us | vsac | ||
| signal.core.r4 | R4 | detailed-race | Detailed Race | active | 2022-09 | us | vsac | ||
| signal.core.r4 | R4 | omb-ethnicity-category | OMB Ethnicity Categories | active | 2022-09 | us | vsac | ||
| hl7.fhir.us.davinci-pcde | R4 | PCDESectionCode | PCDE Document Section Codes | draft | 2022-08 | us | fhir | ||
| ca.on.oh.mha-pds | R4 | vs-TotalHouseholdIncome-v1 | Total Household Income | active | 2022-08 | ca | tho | ||
| fhir.org.nz.ig.base | R4 | location-alias-type | Alias types | active | 2025-06 | us | |||
| hl7.fhir.us.davinci-pas | R4 | X12278FollowUpActionCodes | X12 278 Follow Up Action Value Set | trial-use | 3 | fm | 2025-07 | us | x12 |
| hl7.fhir.us.davinci-pas | R4 | X12278RejectReasonCodes | X12 278 Reject Reason Value Set | trial-use | 3 | fm | 2025-07 | us | x12 |
| hl7.fhir.us.davinci-pas | R4 | X12278DiagnosisCodes | X12 278 Diagnosis Code Value Set | trial-use | 3 | fm | 2025-07 | us | cms tho icd |
| hl7.terminology | R5 | composite-measure-scoring | CompositeMeasureScoring | active | 2 | cqi | 2024-04 | uv | tho |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.173 | Contraception, Counseling | active | 2024-04 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.174 | Contraception, Counseling | active | 2024-04 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.175 | Contraception, Counseling | active | 2024-04 | us | icd | ||
| nictiz.fhir.nl.stu3.questionnaires | R3 | questionnaire-enable-operator | QuestionnaireItemOperator | draft | 3 | fhir | 2019-10 | nl | fhir |
| hl7.terminology | R5 | v3-Currency | Currency | retired | 2014-03 | uv | tho | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-icdo3histologicalgrade | NKRS - ICD-O-3 Histological Grade | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-topographymetastases | NKRS - Topography of Metastases | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-lymphaticinvasion | NKRS - Lymphatic Invasion | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-venousinvasion | NKRS - Venous Invasion | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-sentinellymphnodeassessment | NKRS - Sentinel Lymph Node Assessment | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-luganostaging | NKRS - Lugano Staging | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-diagnosticmethodsused | NKRS - Diagnostic Methods Used | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-cn | NKRS - cN | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-her2receptorstatus | NKRS - Her2 Receptor Status | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-issstaging | NKRS - ISS Staging | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-stjudemurphystaging | NKRS - St. Jude / Murphy Staging | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-serumtumourmarkers | NKRS - Serum Tumour Markers | active | 2022-02 | ch | internal sct | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-tnmstagegroup | NKRS - TNM Stage Group | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-pn | NKRS - pN | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-cm | NKRS - cM | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-pm | NKRS - pM | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-hcg | NKRS - β-hCG | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-ldh | NKRS - LDH | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-methodfirstdetection | NKRS - Method of First Detection | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-diabetesmellitus | NKRS - Diabetes Mellitus | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-liverdisease | NKRS - Liver Disease | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-alphafetoprotein | NKRS - α-fetoprotein | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-typerecurrencetransformation | NKRS - Type of Recurrence/Transformation | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-msuffixofpt | NKRS - m-Suffix of pT | active | 2022-02 | ch | internal | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-ct | NKRS - cT | active | 2022-02 | ch | internal | ||
| signal.core.r4 | R4 | days-of-week | DaysOfWeek | normative | 5 | fhir | 2019-10 | us | fhir |
| hl7.fhir.uv.extensions | R5 | concept-map-equivalence | Concept Map Equivalence Value Set | trial-use | 3 | fhir | 2023-01 | uv | fhir |
| hl7.terminology | R5 | v3-EntityDeterminerDetermined | EntityDeterminerDetermined | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-EntityDeterminerDescribedQuantified | EntityDeterminerDescribedQuantified | retired | 2012-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ParticipationDestination | ParticipationDestination | active | 2014-03 | uv | tho | ||
| Test.Training | R3 | CareConnect-DischargeDestination-1 | NHS Data Model and Dictionary Discharge Destination | draft | 2018-11 | ||||
| hl7.terminology | R5 | v3-ActInvoiceDetailGenericCode | ActInvoiceDetailGenericCode | active | 2014-03 | uv | tho | ||
| hl7.fhir.us.pq-cmc-fda | R5 | pqcmc-representation-types | Representation Types | trial-use | 2 | brr | 2025-07 | us | ncit |
| hl7.fhir.uv.cpg | R4 | cpg-recommendation-direction-vs | CPG Recommendation Direction Value Set | active | cds | 2024-11 | uv | fhir | |
| hl7.terminology | R5 | v3-MaritalStatus | MaritalStatus | active | 2014-03 | uv | tho | ||
| hl7.fhir.uv.emedicinal-product-info | R5 | doseForm | Dose Form | active | 2025-07 | uv | fhir | ||
| hl7.fhir.us.Davinci-drug-formulary | R4 | usdf-DrugTierVS | Drug Tier VS | draft | 2020-01 | us | fhir | ||
| hl7.fhir.us.davinci-drug-formulary | R4 | DrugTierVS | Drug tier of medication in health plan | trial-use | phx | 2025-02 | us | fhir | |
| hl7.fhir.uv.genomics-reporting | R4 | functional-effect-vs | Functional Effect Value Set | trial-use | 2 | cg | 2025-06 | uv | |
| hl7.fhir.fr.core | R4 | fr-core-vs-practitioner-role-exercice | FR Core ValueSet PractitionerRole Exercice | active | 2024-09 | fr | |||
| hl7.terminology | R5 | v3-TransferActReason | TransferActReason | active | 2014-03 | uv | tho | ||
| hl7.fhir.be.medication | R4 | BeMedicationExposureIntentVS | Medication exposure intent | active | 2025-07 | be | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.176 | Methotrexate Injection | active | 2024-04 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.169 | Abortion, Spontaneous / Miscarriage | active | 2024-04 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.171 | Abortion, Spontaneous / Miscarriage | active | 2024-04 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.170 | Abortion, Spontaneous / Miscarriage | active | 2024-04 | us | sct | ||
| hl7.terminology | R5 | v3-ParticipationTargetLocation | ParticipationTargetLocation | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | citation-summary-style | Citation Summary Style | trial-use | 1 | cds | 2025-01 | uv | tho |
| fhir.argonaut.scheduling | R3 | argo-slot-status | Argonaut Slot Status Codes | active | 2018-03 | us | fhir | ||
| hl7.terminology | R5 | verificationresult-need | Need | active | pa | 2024-04 | uv | tho | |
| nhsd.assets.stu3 | R3 | CareConnect-NHSDataDictionary-PersonStatedGender-1 | NHS Data Model and Dictionary Person Stated Gender Code | active | 2017-08 | ||||
| nhsd.assets.stu3 | R3 | NHSDataDictionary-PersonStatedGender-1 | NHS Data Model and Dictionary Person Stated Gender Code | active | 2017-08 | ||||
| fhir.r4.ukcore.stu3.currentbuild | R4 | UKCore-PersonStatedGenderCode | UK Core Person Stated Gender Code | retired | 2021-09 | us | |||
| csiro.fhir.au.smartforms | R4 | administrative-gender | AdministrativeGender | normative | 5 | pa | 2019-10 | au | fhir |
| Test.Training | R3 | CareConnect-AdministrativeGender-1 | Administrative Gender | draft | 5 | pc | 2017-04 | fhir | |
| NHSDigital.FHIR.STU3 | R3 | CareConnect-AdministrativeGender-1 | Administrative Gender | active | 5 | pc | 2017-04 | fhir | |
| hl7.fhir.us.vrdr | R4 | vrdr-administrative-gender-vs | Administrative Gender ValueSet | active | pher | 2024-10 | us | fhir | |
| ca.on.oh-olis | R4 | olis-AdministrativeGender | AdministrativeGender | active | fhir | ||||
| hl7.terminology | R5 | v3-AdministrativeGender | AdministrativeGender | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ActRelationshipHasGeneralization | ActRelationshipHasGeneralization | active | 2014-03 | uv | tho | ||
| ch.fhir.ig.ch-crl | R4 | nkrs-treatmentgoal | NKRS - Treatment Goal | active | 2022-02 | ch | sct | ||
| hl7.fhir.uv.extensions.r3 | R3 | variable-handling | Evidence Variable Handling | trial-use | 5 | cds | 2020-12 | uv | fhir |
| hl7.terminology | R5 | statistic-model-code | Statistic Model Code | trial-use | 1 | cds | 2025-01 | uv | tho |
| ca.on.oh.mha-pds | R4 | vs-HighestLevelOfEducationAttained-v1 | Highest Level of Education Attained | active | 2022-08 | ca | sct tho | ||
| ca.on.oh.mha-pds | R4 | ValueSet.encounter-identifier-system | EncounterIdentifierValueSet | active | 2022-08 | ca | |||
| ca.on.oh.mha-pds | R4 | ValueSet.patient-jhn-identifier-system | PatientJHNIdentifierSystem | active | 2022-08 | ca | |||
| ca.on.oh.mha-pds | R4 | ValueSet.patient-mrn-identifier-system | PatientMRNIdentifierSystem | active | 2022-08 | ca | |||
| ca.on.oh.mha-pds | R4 | ValueSet.patient-episode-of-care-identifier-system | EpisodeOfCareIdentifierValueSet | active | 2022-08 | ca | |||
| ca.on.oh.mha-pds | R4 | ValueSet.ServiceRequest-identifier-system | ServiceRequestIdentifierValueSet | active | 2022-08 | ca | |||
| hl7.fhir.us.ecr | R4 | us-ph-message-significance-category | US Public Health Message Significance Category | trial-use | 1 | pher | 2019-10 | us | fhir |
| hl7.fhir.us.ph-library | R4 | us-ph-valueset-message-significance-category | US Public Health ValueSet - Message Significance Category | trial-use | 1 | inm | 2019-10 | us | fhir |
| hl7.terminology | R5 | v3-FirstFillPharmacySupplyType | FirstFillPharmacySupplyType | active | 2014-03 | uv | tho | ||
| ca.on.dhdr.r4.v4 | R4 | EncounterType | Encounter Type | active | 2019-02 | us | |||
| hl7.terminology | R5 | measure-data-usage | MeasureDataUsage | active | 2 | cqi | 2024-04 | uv | tho |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1147.135 | Bleeding at Critical Site | active | 2021-06 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1147.145 | Bleeding at Non Critical Site | active | 2025-02 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1147.143 | Bleeding at Critical Site | active | 2021-06 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1147.125 | Bleeding at Non Critical Site | active | 2025-02 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1147.146 | Bleeding at Non Critical Site | active | 2021-06 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1147.144 | Bleeding at Critical Site | active | 2021-06 | us | vsac | ||
| hl7.fhir.nz.cca | R4 | sact-treatment-intent-code | Treatment intent | active | 2020-11 | nz | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1206.12 | Opioid (Oral Tablets and Patches only) | active | 2019-12 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.117.1.7.1.1 | Major Surgical Procedure | active | 2025-02 | us | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.666.5.1250 | Major Surgical Procedure | active | 2025-02 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1115.11 | Care Experience Preferences Grouping | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1115.9 | Treatment Intervention Preferences Grouping | active | 2024-03 | us | vsac | ||
| hl7.terminology | R5 | v3-ActSubstanceAdministrationImmunizationCode | ActSubstanceAdministrationImmunizationCode | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-AdjudicatedWithAdjustments | AdjudicatedWithAdjustments | active | 2014-03 | uv | tho | ||
| fhir.r4.wales.discovery | R4 | DataStandardsWales-JobRole | Data Standards Wales Job Role | retired | 2021-08 | us | |||
| hl7.fhir.uv.phenomics-exchange | R4 | KaryotypicSex | Karyotypic sex value set | draft | cic | 2021-05 | uv | fhir | |
| hl7.terminology | R5 | dose-rate-type | DoseAndRateType | draft | 1 | fhir | 2020-02 | uv | tho |
| hl7.fhir.uv.extensions.r4b | R4B | device-specification-category | Device Specification Category | trial-use | 2 | oo | 2022-03 | uv | fhir |
| hl7.terminology | R5 | v3-VaccineType | VaccineType | active | 2014-03 | uv | tho | ||
| hl7.fhir.uv.extensions.r3 | R3 | spdx-license | S P D X License | trial-use | 4 | fhir | 2020-12 | uv | fhir |
| ch.fhir.ig.ch-term | R4 | ch-vacd-swissmedic-imunglobuline-vs | CH VACD Swissmedic Authorized Immunglobuline Codes | active | 2025-05 | ch | internal | ||
| ch.fhir.ig.ch-term | R4 | ch-vacd-swissmedic-imunsera-vs | CH VACD Swissmedic Authorized Immunsera Codes | active | 2025-05 | ch | internal | ||
| hl7.fhir.us.covid19library | R4 | state-codes-vs | State Codes Value Set | active | 2022-07 | us | sct | ||
| hl7.fhir.ca.baseline | R4 | prescriptionmedicinalproduct | Prescription Medicinal Product | draft | 2025-05 | ca | |||
| hl7.fhir.ca.baseline | R4 | prescriptiondrugform | Prescription Drug Form | draft | 2025-05 | ca | |||
| hl7.fhir.uv.sdc | R4 | dex-mimetype | DEX mapping language mime types | informative | fhir | 2025-08 | uv | ietf | |
| ch.fhir.ig.ch-term | R4 | ch-vacd-vaccines-snomedct-vs | CH VACD Snomed CT for VaccineCode | active | 2025-05 | ch | sct | ||
| ch.fhir.ig.ch-term | R4 | ch-vacd-vaccines-vs | CH VACD Swissmedic code for VaccineCode | active | 2025-05 | ch | sct | ||
| ch.fhir.ig.ch-term | R4 | snomedct-concept-viraldiseases-vs | Snomed CT Concept Viral Diseases | active | 2025-05 | ch | sct | ||
| signal.core.r4 | R4 | questionnaire-dacods-living-situation | Questionnaire DACODS Living Situation | draft | 1 | pa | us | ||
| hl7.terminology | R5 | v3-ParticipationOrigin | ParticipationOrigin | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-VaccineManufacturer | VaccineManufacturer | active | 2014-03 | uv | tho | ||
| hl7.fhir.us.vrdr | R4 | vrdr-death-certification-event-max-vs | Event Code for Death Certificate Composition - Max | active | pher | 2024-10 | us | fhir sct | |
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.4057 | Emergency Department Encounter | active | 2020-07 | us | cpt | ||
| ch.fhir.ig.ch-vacd | R4 | ch-vacd-risks-vs | Swiss Risks For Immunizations | active | 2025-05 | ch | internal | ||
| ch.fhir.ig.ch-vacd | R4 | ch-vacd-risks-medical-vs | Swiss Medical Risks For Immunizations | active | 2025-05 | ch | sct | ||
| Test.Training | R3 | CareConnect-AdmissionMethod-1 | NHS Data Model and Dictionary Admission Method | draft | 2018-11 | ||||
| Test.Training | R3 | CareConnect-DischargeMethod-1 | NHS Data Model and Dictionary Discharge Method | draft | 2018-11 | ||||
| hl7.fhir.us.breastcancer | R3 | oncology-LymphNodeClinicalMethodVS | BC LymphNodeClinicalMethodVS ValueSet | draft | 2018-08 | us | sct | ||
| hl7.terminology | R5 | v3-xActFinancialProductAcquisitionCode | x_ActFinancialProductAcquisitionCode | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | v3-ActProductAcquisitionCode | ActProductAcquisitionCode | active | 2014-03 | uv | tho | ||
| hl7.terminology | R5 | characteristic-method | CharacteristicMethod | draft | 1 | cds | 2020-02 | uv | tho |
| hl7.fhir.us.breastcancer | R3 | oncology-BreastCancerDetectionVS | BC BreastCancerDetectionVS ValueSet | draft | 2018-08 | us | sct | ||
| hl7.terminology | R5 | service-referral-method | ReferralMethod | active | 1 | pa | 2024-04 | uv | tho |
| signal.core.r4 | R4 | service-referral-method | ReferralMethod | draft | 1 | pa | 2019-10 | us | tho |
| hl7.fhir.uv.extensions | R5 | major-fhir-version | Major FHIR Versions | trial-use | 3 | fhir | 2025-08 | uv | fhir |
FHIR